ADVFN Logo ADVFN

Não encontramos resultados para:
Verifique se escreveu corretamente ou tente ampliar sua busca.

Tendências Agora

Rankings

Parece que você não está logado.
Clique no botão abaixo para fazer login e ver seu histórico recente.

Cadastre-se

Já é membro? Faça login

Moneta Markets

Abrir Conta

Moneta Markets
Dados
Notícias
Ferramentas
Mercados
Comunidade

Hot Features

Follow Feed

Conecte-se com traders e investidores em nossa comunidade Follow Feed.

Fluxo de Opções

Explore dados abrangentes de opções e utilize filtros avançados com Fluxo de Opções.

Monitor

Organize e monitore sua lista de ações e ativos com o Monitor.
Entrar Premium IconPremium Help Menu
Índice Bovespa
120.767,19
-1,73%
S&P 500
5.346,99
-0,11%
US Dollar vs BRL
5,29355
-0,98%
Bitcoin
69.363,85
0,05%
Brent Oil
79,395
0,00%
Registration Strip Icon for default Cadastre-se gratuitamente para obter cotações em tempo real, gráficos interativos, fluxo de opções ao vivo e muito mais.
Cadastre-se
  1. Início
  2. Investir
  3. Ações
  4. EUA
  5. NASDAQ
  6. Cyclacel Pharmaceuticals Inc (CYCC)

  7. Cyclacel Pharmaceuticals Inc (CYCC) Notícias

CYCC

Cyclacel Pharmaceuticals (CYCC)

Cyclacel Pharmaceuticals Inc
De:
Ordenação:
 Apresentando as notícias mais relevantes sobre:NASDAQ:CYCC
DataHoraFonteTítuloCódigoCompanhia
04/06/202409:00GlobeNewswire Inc.Cyclacel’s Fadraciclib Demonstrates Efficacy in Patient-Derived Colorectal Cancer Models at the 2024 ASCO Annual MeetingNASDAQ:CYCCCyclacel Pharmaceuticals Inc
03/06/202409:00GlobeNewswire Inc.Cyclacel Pharmaceuticals Reports New Clinical Data at 2024 ASCO Annual Meeting Highlighting Oral Fadraciclib’s Potential as a Precision Medicine for CancerNASDAQ:CYCCCyclacel Pharmaceuticals Inc
14/05/202417:05GlobeNewswire Inc.Cyclacel Pharmaceuticals Reports First Quarter Financial Results and Provides Business UpdateNASDAQ:CYCCCyclacel Pharmaceuticals Inc
08/05/202410:15GlobeNewswire Inc.Cyclacel Pharmaceuticals to Release First Quarter 2024 Financial ResultsNASDAQ:CYCCCyclacel Pharmaceuticals Inc
02/05/202417:30GlobeNewswire Inc.Cyclacel Pharmaceuticals Announces Closing of $8.0 Million Private Placement Priced At-The-Market Under NASDAQ RulesNASDAQ:CYCCCyclacel Pharmaceuticals Inc
30/04/202414:51AllPennyStocks.com$8 Million Private Placement Announcement Sends Biotech FlyingNASDAQ:CYCCCyclacel Pharmaceuticals Inc
30/04/202408:00GlobeNewswire Inc.Cyclacel Pharmaceuticals Announces $8.0 Million Private Placement Priced At-The-Market Under Nasdaq RulesNASDAQ:CYCCCyclacel Pharmaceuticals Inc
01/04/202410:15GlobeNewswire Inc.Cyclacel Pharmaceuticals to Present New Clinical Data at 2024 ASCO Annual Meeting Highlighting Fadraciclib’s Potential as a Precision Medicine for CancerNASDAQ:CYCCCyclacel Pharmaceuticals Inc
19/03/202417:05GlobeNewswire Inc.Cyclacel Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business UpdateNASDAQ:CYCCCyclacel Pharmaceuticals Inc
19/03/202408:27IH Market NewsUS Index Futures Decline Ahead of Federal Reserve Meeting, Oil Prices RetreatNASDAQ:CYCCCyclacel Pharmaceuticals Inc
13/03/202417:05GlobeNewswire Inc.Cyclacel Pharmaceuticals to Release Fourth Quarter and Full Year 2023 Financial ResultsNASDAQ:CYCCCyclacel Pharmaceuticals Inc
07/03/202411:15GlobeNewswire Inc.Cyclacel Pharmaceuticals Announces Preclinical Proof-of-Concept Data for Fadraciclib to be Presented at the American Association for Cancer Research (AACR) Annual Meeting 2024NASDAQ:CYCCCyclacel Pharmaceuticals Inc
06/03/202411:15GlobeNewswire Inc.Cyclacel Pharmaceuticals Announces Receipt of $2.9 Million R&D Tax CreditNASDAQ:CYCCCyclacel Pharmaceuticals Inc
20/02/202411:15GlobeNewswire Inc.Cyclacel Pharmaceuticals to Participate in 2024 BIO CEO & Investor ConferenceNASDAQ:CYCCCyclacel Pharmaceuticals Inc
30/01/202411:15GlobeNewswire Inc.Cyclacel Pharmaceuticals Announces the Appointment of Brian Schwartz, M.D. as Chief Medical OfficerNASDAQ:CYCCCyclacel Pharmaceuticals Inc
18/12/202311:00GlobeNewswire Inc.Cyclacel Pharmaceuticals Reports Fadraciclib Phase 1 Data Suggesting Efficacy Against Tumors With CDKN2A, CDKN2B and MTAP DeletionsNASDAQ:CYCCCyclacel Pharmaceuticals Inc
12/12/202318:05GlobeNewswire Inc.Cyclacel Pharmaceuticals Announces Reverse Stock SplitNASDAQ:CYCCCyclacel Pharmaceuticals Inc
30/11/202311:15GlobeNewswire Inc.Cyclacel Regains Compliance With Nasdaq Listing Rule Following Filing of Its Form 10-Q With the SECNASDAQ:CYCCCyclacel Pharmaceuticals Inc
28/11/202319:15GlobeNewswire Inc.Cyclacel Receives Notification of Deficiency From Nasdaq Regarding Timely Filing of Quarterly Report on Form 10-QNASDAQ:CYCCCyclacel Pharmaceuticals Inc
07/11/202311:15GlobeNewswire Inc.Cyclacel Pharmaceuticals to Release Third Quarter 2023 Financial ResultsNASDAQ:CYCCCyclacel Pharmaceuticals Inc
09/08/202317:05GlobeNewswire Inc.Cyclacel Pharmaceuticals Reports Second Quarter Financial Results and Provides Business UpdateNASDAQ:CYCCCyclacel Pharmaceuticals Inc
03/08/202310:15GlobeNewswire Inc.Cyclacel Pharmaceuticals to Release Second Quarter 2023 Financial ResultsNASDAQ:CYCCCyclacel Pharmaceuticals Inc
14/06/202317:06Edgar (US Regulatory)Current Report Filing (8-k)NASDAQ:CYCCCyclacel Pharmaceuticals Inc
11/05/202318:16Edgar (US Regulatory)Quarterly Report (10-q)NASDAQ:CYCCCyclacel Pharmaceuticals Inc
04/05/202310:15GlobeNewswire Inc.Cyclacel Pharmaceuticals to Release First Quarter 2023 Financial ResultsNASDAQ:CYCCCyclacel Pharmaceuticals Inc
03/05/202310:15GlobeNewswire Inc.Cyclacel Pharmaceuticals Announces Receipt of $4.7 Million R&D Tax CreditNASDAQ:CYCCCyclacel Pharmaceuticals Inc
08/03/202319:03Edgar (US Regulatory)Annual Report (10-k)NASDAQ:CYCCCyclacel Pharmaceuticals Inc
14/02/202318:56Edgar (US Regulatory)Statement of Ownership (sc 13g)NASDAQ:CYCCCyclacel Pharmaceuticals Inc
06/02/202313:27Edgar (US Regulatory)Amended Statement of Ownership (sc 13g/a)NASDAQ:CYCCCyclacel Pharmaceuticals Inc
02/02/202318:20Edgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:CYCCCyclacel Pharmaceuticals Inc
 Apresentando as notícias mais relevantes sobre:NASDAQ:CYCC

Seu Histórico Recente

ASX
ANZIOB
COIN
PFIETH
Protocol Finance
BOV
SEED13
Seedel Tecnologia Ltda
HUOB
SOFIUSDT
Rai.Finance
BIT
FLXE
Franklin Temp ICAV - Fra...
EU
SPEUS
BNP Paribas Easy S&P 500...
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

Brasil
Empresa
Negócios
Popular
Obter o aplicativo
App Store
Google Play

Suporte: (11) 4950 5808 | suporte@advfn.com.br

Ao acessar os serviços da ADVFN você estará de acordo com os Termos e Condições

© 2024 ADVFN PLC - Todos os direitos reservados